Living with Crohn's disease can be a daily struggle, filled with pain and uncertainty. Many patients find that current treatments either don't work or lose their effectiveness over time, leaving them searching for new solutions. This study is investigating a combination of two promising drugs, vedolizumab and either adalimumab or ustekinumab, to see if they can provide better relief for adults with moderate to severe Crohn's disease. Participants will first receive the combination treatment, and those who respond will continue with vedolizumab alone. The goal is to assess how well these treatments work in reducing inflammation in the intestines, which is a key factor in managing Crohn's disease. If these new combinations prove effective, they could offer hope to many patients who feel stuck in their current treatment journey. However, it's important to remember that this is still a study, and results will take time to analyze. For now, the potential for better options is on the horizon, bringing a glimmer of hope to those affected by this challenging condition.
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Plain Language Summary
What this means for you:
New drug combinations may soon provide hope for better Crohn's disease management and relief. What this means for you:
New drug combinations may soon provide hope for better Crohn's disease management and relief. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE4
Condition(s): Crohn's Disease
Intervention(s): Vedolizumab (DRUG), Adalimumab (DRUG), Ustekinumab (DRUG), Ustekinumab (DRUG)
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment.
The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A.
Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Detailed: The drug being tested in this study is vedolizumab. Vedolizumab is being tested to treat people with moderate to severe Crohn's disease who have experienced inadequate response, loss of response or intolerance to either one prior interleukin \[IL\] antagonist, and no other biologic/small molecule (Group A); one IL antagonist and either one Janus kinase inhibitor (JAKi) or one TNFi (other than adalimumab) \[Group B\] (Cohort 1) or one prior tumor necrosis factor inhibitor \[TNFi\] and no other biologic/small molecule (Group C); one TNFi and either 1 JAKi or one IL antagonist (other than UST) (Group D) (Cohort 2). The study will look at the efficacy and safety of dual targeted therapy.
The study will enroll approximately 100 participants. Participants will be assigned to one of the two trea
Primary Outcome(s): Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26; Part B: Percentage of Participants With an Endoscopic Response Based on the SES-CD at Week 52
Enrollment: 100 (ESTIMATED)
Lead Sponsor: Takeda
Start: 2024-04-18 | Primary Completion: 2027-06-28